EDIT - Company ID 0001650664
The table below shows Editas Medicine, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$23.06M | -$47.80M | -$49.87M | -$35.77M | -$49.23M | -$49.48M |
| Capital expenditure | $92.00K | $114.00K | $1.87M | $1.84M | $2.25M | $84.00K |
| Investing cash flow | $64.00K | $56.39M | -$4.75M | $23.27M | $56.37M | $3.24M |
| Dividends paid | - | - | - | - |
Editas Medicine, Inc. reported operating cash flow of -$165.24M for fiscal year 2025. That is up 21.4% from -$210.28M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$50.25M (FY 2016) to -$165.24M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $0.00 | -$1.44M | $192.00K | $0.00 | $218.00K | $261.47M |